$Autolus Therapeutics (AUTL.US)$ First regulatory approval validates Autolus' technology platform and establishes commercial pathway, though NICE approval remains critical next step. This MHRA conditional authorization represents a transformative milestone for Autolus Therapeutics, validating both their lead product and underlying technology platform. As the company's first regulatory approval, it establishes Autolus as an emerging commercial-stage biopharmaceutic...
$Autolus Therapeutics (AUTL.US)$ MHRA approval of AUCATZYL for r/r B-ALL represents significant treatment advance with impressive 76.6% response rate and manageable safety profile. The MHRA's conditional authorization of AUCATZYL marks a critical advancement for adult patients with r/r B-ALL, a disease with historically poor outcomes. The FELIX study results are compelling, showing a 76.6% complete response rate in the pivotal cohort, with 21.2 months median response dur...
$Autolus Therapeutics (AUTL.US)$Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes! February 12 to 15, 2025
$Autolus Therapeutics (AUTL.US)$ Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
$Autolus Therapeutics (AUTL.US)$Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 6 to 8 PM pst 12/9/24! 4 MINUTES AGO, 7:30 PM EST VIA GLOBENEWSWIRE
Daily Investors
:
Now they had their PDUFA Meetings, but that's the risk we try. It's always better for nothing, then to get a major disappointment and catastrophic loss
Trytosaveabit
:
Not sure how it performs compared to GILEAD’S TECARTUS? Do you know? Is it better? Safer? Cheaper? I didn’t get to deep in the data! But you are my Dr so ima ask you first!
Trytosaveabit
Jaguar8
OP
:
Oh brother thank you! But please you ain’t gotta do that! I was just figuring you may have already had some info about the drug that’s all! Please don’t trouble yourself! Just rest up please!
Jaguar8
OPTrytosaveabit
:
So Aucatzyl has overall complete remission of 63% compared to 62% of Tecartus. Aucatzyl has no picing yet but Tecartus is 373,000 USD per infusion
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Autolus Therapeutics Stock Discussion
First regulatory approval validates Autolus' technology platform and establishes commercial pathway, though NICE approval remains critical next step.
This MHRA conditional authorization represents a transformative milestone for Autolus Therapeutics, validating both their lead product and underlying technology platform. As the company's first regulatory approval, it establishes Autolus as an emerging commercial-stage biopharmaceutic...
MHRA approval of AUCATZYL for r/r B-ALL represents significant treatment advance with impressive 76.6% response rate and manageable safety profile.
The MHRA's conditional authorization of AUCATZYL marks a critical advancement for adult patients with r/r B-ALL, a disease with historically poor outcomes. The FELIX study results are compelling, showing a 76.6% complete response rate in the pivotal cohort, with 21.2 months median response dur...
Revolutionary Leukemia Treatment: Autolus's CAR-T Therapy Secures First-Ever UK Approval with 77% Success Rate
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
ya I'm getting in here
No comment yet